GlobeNewsWire · IMCR · November 6, 2026

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

Get the app for more

Explore stock news, insights and company research.